FMP

FMP

Enter

NBSE - NeuBase Therapeutics...

Financial Summary of NeuBase Therapeutics, Inc.(NBSE), NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the developme

photo-url-https://financialmodelingprep.com/image-stock/NBSE.png

NeuBase Therapeutics, Inc.

NBSE

NASDAQ

Inactive Equity

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

0.378 USD

-0.006 (-1.59%)

About

ceo

Mr. Todd P. Branning

sector

Healthcare

industry

Biotechnology

website

https://www.neubasetherapeutics.com

exchange

NASDAQ

Description

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pi...

CIK

0001173281

ISIN

US64132K2015

CUSIP

64132K102

Address

350 Technology Drive

Phone

646 450 1790

Country

US

Employee

37

IPO Date

May 28, 2004

Summary

CIK

0001173281

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

64132K102

ISIN

US64132K2015

Country

US

Price

0.38

Beta

0.94

Volume Avg.

245.21k

Market Cap

1.42M

Shares

-

52-Week

0.36-4.8

DCF

10.63

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.02

P/B

-

Website

https://www.neubasetherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest NBSE News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep